Accurate detection of homozygous CDKN2A deletion in meningioma represents a critical turning point in neuro-oncology diagnostics. The fifth edition of the World Health Organization classification established that biallelic loss of this tumor suppressor gene defines anaplastic, grade 3 behavior. Consequently, oncologists and neuropathologists rely heavily on diagnostic tools to identify this crucial marker before selecting aggressive adjuvant therapies.

Molecular Significance of CDKN2A Deletion in Meningioma

Meningiomas represent the most prevalent primary intracranial neoplasms encountered in adult clinical practice. Although most cases exhibit benign histological patterns, high-grade variants carry significant risks of early recurrence and patient mortality. Therefore, the 2021 WHO classification introduced objective molecular criteria to improve risk stratification across all histological subtypes. Under these updated guidelines, homozygous CDKN2A loss directly establishes a CNS WHO grade 3 diagnosis. This classification applies regardless of whether the tissue exhibits traditional microscopic features of anaplasia or elevated mitotic counts. The CDKN2A gene encodes the p16INK4a protein, which governs critical cell cycle arrest at the G1-S checkpoint. Loss of this regulatory brake unleashes rapid cellular proliferation and promotes aggressive tumor growth. Moreover, patients harboring this genetic lesion experience drastically shortened recurrence-free survival intervals. Reliable detection directly influences neuro-oncological management, including the prompt delivery of adjuvant radiotherapy and intensified neuroimaging surveillance. Consequently, neuropathologists must employ validated diagnostic methods to avoid underestimating true biological aggressiveness and misclassifying lethal malignancies.

Diagnostic Dilemmas with Surrogate Immunohistochemistry

Many pathology laboratories utilize immunohistochemical assays as practical, cost-effective surrogates for expensive molecular sequencing. Specifically, pathologists evaluate p16 and methylthioadenosine phosphorylase protein expression to infer the underlying copy number status. The MTAP gene resides adjacent to CDKN2A on chromosome 9p21.3. Because large chromosomal deletions often encompass both loci, researchers initially considered MTAP loss a dependable proxy for homozygous CDKN2A deletion. However, clinical investigations reveal significant pitfalls when teams rely exclusively on immunohistochemistry. For example, p16 staining patterns vary considerably across tissue sections due to background stromal entrapment and variable ischemic fixation artifacts. Moreover, non-neoplastic vascular endothelial cells retain robust p16 expression, confounding qualitative microscopic interpretation. Similarly, retained MTAP immunoreactivity does not guarantee intact CDKN2A alleles. Recent clinical studies show that relying solely on immunohistochemical surrogates leads to erroneous tumor grading. Therefore, while loss of expression provides helpful diagnostic clues, intact protein staining cannot safely rule out an underlying homozygous deletion. Diagnostic teams must interpret surrogate immunohistochemistry with extreme caution.

Discordance Between MTAP Expression and Biallelic Deletion

A recent investigation evaluated the concordance between molecular testing and surrogate protein expression in anaplastic meningioma specimens. Strikingly, investigators identified persistent MTAP protein expression in one-third of tumors that harbored confirmed homozygous CDKN2A deletions. Detailed genetic characterization explained this apparent paradox. In each discordant case, the deletion breakpoint spared one copy of MTAP while completely deleting both CDKN2A alleles. Consequently, the tumor cells carried a hemizygous MTAP deletion alongside homozygous CDKN2A loss. Because a single functional allele remains sufficient for protein synthesis, immunohistochemistry demonstrated intact MTAP expression. Thus, pathologists observing positive MTAP staining might incorrectly assume that the adjacent tumor suppressor remains preserved. This diagnostic oversight carries profound consequences, as clinicians would mistakenly classify a malignant grade 3 meningioma as a lower-grade neoplasm. Furthermore, this discrepancy underscores the fundamental limitation of assuming uniform co-deletion across the entire 9p21.3 region. Pathologists must recognize that retained MTAP immunoreactivity never provides definitive proof of preserved CDKN2A status. Misleading protein retention can tragically delay appropriate neuro-oncological treatment.

Technical Challenges in FISH and Dual-Probe Testing

Fluorescence in situ hybridization serves as a widely accepted cytogenetic tool across diagnostic oncology centers. However, FISH analysis in high-grade meningiomas presents notable technical challenges and interpretive hazards. Diagnostic laboratories frequently utilize commercial dual-color probes designed to hybridize across the broad 9p21 region. In many commercial probe designs, the fluorescent signal covers both the CDKN2A and MTAP loci simultaneously. When a specimen harbors homozygous CDKN2A deletion accompanied by hemizygous MTAP retention, the hybridized probe can still emit a discernible fluorescent signal. Consequently, the microscopist may interpret the sample as harboring a simple hemizygous loss rather than a lethal biallelic deletion. Additionally, nuclear truncation artifacts, dense tumor cellularity, and overlapping nuclei complicate signal enumeration in paraffin-embedded sections. Furthermore, intratumoral heterogeneity can obscure focal homozygous deletions within broader fields of diploid stromal cells. Therefore, while FISH offers valuable diagnostic support, dual-probe designs can produce misleading results unless laboratories deploy probes with strict locus specificity. Overreliance on broad hybridization probes creates substantial diagnostic vulnerability.

Advancing to Quantitative Molecular Copy Number Profiling

To eliminate the diagnostic vulnerabilities of surrogate immunohistochemistry and ambiguous FISH signals, institutions are transitioning toward quantitative molecular assays. Modern high-resolution chromosomal microarrays and molecular inversion probe analyses accurately measure absolute genomic copy numbers across every exon. Similarly, targeted next-generation sequencing assays with specialized bioinformatic copy-number algorithms precisely delineate genomic breakpoints at 9p21.3. Moreover, genome-wide DNA methylation profiling provides robust, objective tumor classification while simultaneously generating detailed copy number variation plots. These advanced platforms easily distinguish between focal homozygous deletions, broad hemizygous losses, and balanced diploid states. Because treatment paradigms differ dramatically between WHO grades, precise genomic characterization remains essential for every aggressive meningioma. Adjuvant external beam radiotherapy and enrollment in targeted clinical trials depend entirely on this distinction. In addition, molecular confirmation prevents overtreatment in cases that demonstrate misleading immunohistochemical loss caused by poor pre-analytical tissue handling. Thus, comprehensive molecular profiling establishes the highest diagnostic standard in neuro-oncology practice and guarantees diagnostic precision.

Strategic Diagnostic Algorithms for High-Grade Meningiomas

Establishing an efficient, tiered diagnostic workflow ensures accurate patient risk stratification while maintaining laboratory stewardship. Neuropathologists should evaluate both p16 and MTAP immunohistochemistry as preliminary screening tools during routine workups. When a high-grade meningioma demonstrates complete loss of p16 or MTAP expression, pathologists must immediately initiate molecular reflex testing to verify homozygous deletion. Conversely, pathologists must remember that retained MTAP staining does not rule out biallelic loss of CDKN2A. Therefore, any tumor displaying atypical histological features, brain invasion, or high proliferative activity warrants confirmatory genomic analysis regardless of staining patterns. Multidisciplinary neuro-oncology tumor boards must critically review the specific diagnostic methodology before establishing definitive treatment plans. When surgical margins are subtotal, misdiagnosing a grade 3 tumor as grade 2 can inappropriately delay essential adjuvant radiation. Furthermore, emerging clinical trials investigating CDK4/6 inhibitors and PRMT5 inhibitors require exact genomic documentation for patient eligibility. Through rigorous genomic confirmation, clinicians ensure personalized, evidence-based management for every patient facing aggressive cranial neoplasms.

Frequently Asked Questions

Why is MTAP immunohistochemistry unreliable as a sole surrogate?

MTAP immunohistochemistry frequently fails as an exclusive surrogate because MTAP can remain expressed when only hemizygously deleted, even alongside homozygous CDKN2A loss. Consequently, intact MTAP staining creates a false-negative impression of intact 9p21.3 status. Clinicians must not rely entirely on MTAP expression to exclude high-grade anaplastic disease.

How does the 2021 WHO classification incorporate CDKN2A alterations?

The 2021 WHO classification designates any meningioma harboring a homozygous CDKN2A deletion as CNS WHO grade 3, regardless of histopathological features. Because homozygous loss portends early recurrence and aggressive tumor progression, precise identification directly dictates adjuvant therapy, surgical margins, and closer post-operative radiological surveillance protocols.

Which molecular techniques provide the most accurate copy number assessment?

Quantitative high-resolution platforms offer the most dependable assessment of copy number variations at the 9p21.3 locus. Specifically, DNA methylation profiling, targeted next-generation sequencing, and molecular inversion probe arrays accurately distinguish hemizygous from homozygous deletions. These genomic methods overcome optical hybridization artifacts often encountered during routine dual-color fluorescence in situ hybridization.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should exercise their independent clinical judgment when interpreting diagnostic findings. Refer to the latest local and national guidelines for clinical practice.

References

1. Zschernack V et al. Pitfalls in the evaluation of CDKN2A copy number status in meningioma. J Neurooncol. 2025 Jul. doi: 10.1007/s11060-025-05029-6. PMID: 40227557.
2. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251.
3. Sievers P, Hielscher T, Schrimpf D, et al. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol. 2020;140(3):409-413.